BML (4694) Q4 2026 earnings summary

Executive summary

• Net sales rose 4.9% year-over-year to ¥150,262 million, driven by new customer acquisition and price optimization.

• Operating profit increased 11.3% to ¥10,421 million, and profit attributable to owners of parent surged 23.7% to ¥7,748 million.

• Growth was supported by steady performance in clinical testing, food hygiene, and medical informatics segments.

Financial highlights

• Gross profit grew to ¥48,689 million from ¥45,861 million year-over-year.

• Ordinary profit reached ¥11,014 million, up 10.5% year-over-year.

• Comprehensive income increased 22.2% to ¥8,823 million.

• Cash and cash equivalents at year-end were ¥64,602 million, up ¥673 million from the prior year.

• Dividend per share for FY2025 was ¥125.00, with a payout ratio of 66.9%.

Outlook and guidance

• FY2026 forecast: net sales of ¥155,000 million (+3.2%), operating profit of ¥10,500 million (+0.8%), and profit attributable to owners of parent of ¥7,000 million (-9.7%).

• Company aims to improve profitability through service fee adjustments and operational efficiency.

• Ninth Medium-Term Management Plan targets enhanced quality, solutions, and mutual development.